FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1552873049> ?p ?o ?g. }

• W1552873049 endingPage "587" @default.
• W1552873049 startingPage "586" @default.
• W1552873049 abstract "Mammalian Target of rapamycine (mTOR) inhibitors are effective in preventing acute rejection in renal as also cardiac transplantations, causing less nephrotoxicity than calcineurin inhibitors (CNI) and benefit in prevention of post-transplant malignancies [1, 2]. However, proteinuria and worsening of renal function have been reported after switchover from CNI to sirolimus in renal transplantation [3]. There are few data on renal function evaluation with everolimus. We report a case of decrease in proteinuria after switching over from sirolimus to everolimus in a liver transplant recipient with diabetic nephropathy. A 63-year-old male with type 2 diabetes underwent a liver transplantation (LT) for alcoholic cirrhosis in 1996. Immunosuppressive treatment combined initially tacrolimus and corticosteroids. Steroids were stopped 3 years post-LT. Because of diabetes, proteinuria was monitored annually. Until December 2005, there was a mild renal dysfunction and microalbuminuria (Fig. 1). Evaluation of creatininemia and proteinuria before and after everolimus introduction. In 2000, a spinocellular carcinoma of the scalp in this patient was treated by surgical resection. Spinocellular carcinoma recurrences were then observed, requiring surgical treatments, external radiotherapy and autologous cutaneous graft. Sirolimus was introduced in June 2006 and tacrolimus was stopped. At sirolimus initiation, creatininemia was 127 μmol/l, Cockcroft-Gault-calculated creatininemia clearance 51 ml/min/1.73 m2, and microalbuminuria 0.15 g/day. Liver function, hepatic and renal echographies were normal. In February 2007, edema of the face and of the legs appeared. Laboratory data showed anemia, proteinuria over 3 g/day without hypoprotidemia [62 g/l (normal values 60–75 g/l)] or hypoalbuminemia [36 g/l (normal values 32–52 g/l)], and mild increase of creatininemia to 150 μmol/l. Sirolimus trough levels were between 3.8 and 8 ng/ml. Sirolimus dosage was then decreased. The other treatments consisted of insulin, pravastatin, allopurinol, nicardipine and candesartan cilexetil, unchanged for more than 1 year. One month later, edema disappeared without biologic improvement. A renal biopsy was performed, revealing diabetic nephropathy without sign of sirolimus toxicity. However, sirolimus was stopped and there was switchover to everolimus administration in June 2007. Six months later, clinical examination was normal. Renal function was stable and proteinuria decreased to 0.39 and 0.28 g/day. Everolimus trough levels were 3.4–11 ng/ml. Liver function remained normal and no spinocellular carcinoma recurrence was observed. Sirolimus-induced proteinuria is a well-known adverse event. In recipients with chronic renal allograft dysfunction treated by sirolimus, increase of proteinuria has been reported in 25–50% of the renal allograft recipients [4-6]. In cardiac transplantation, the incidence was 15%, mainly in cardiac recipients with the previous altered renal function or diabetic nephropathy [7]. However, it seems uncommon in liver transplant recipients [8]. Proteinuria over 300 mg/day has also been described in 39% of renal transplants treated with everolimus [9]. Currently, there was no data on the capacity of everolimus to induce proteinuria in heart or liver transplant recipients [10, 11]. mTOR inhibitors could be less nephrotoxic for native kidney than for renal allograft. Moreover, despite common mechanisms of action, everolimus and sirolimus have different molecular structure and pharmacologic properties and could have also different side-effects. We report a case of rapid decrease of proteinuria after switching from sirolimus to everolimus in a liver transplant recipient; others have described a favorable outcome of interstitial pneumonia after switching from sirolimus to everolimus [12]. To sum up, some patients may benefit from a switching over to mTOR inhibitor, and some sirolimus-side effects could be improved by switching over to everolimus. Further studies are necessary to confirm this observation." @default.
• W1552873049 created "2016-06-24" @default.
• W1552873049 creator A5015978541 @default.
• W1552873049 creator A5025700937 @default.
• W1552873049 creator A5066528943 @default.
• W1552873049 creator A5074388120 @default.
• W1552873049 creator A5076879743 @default.
• W1552873049 date "2008-11-25" @default.
• W1552873049 modified "2023-10-18" @default.
• W1552873049 title "Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy" @default.
• W1552873049 cites W1989514204 @default.
• W1552873049 cites W2012783381 @default.
• W1552873049 cites W2020767402 @default.
• W1552873049 cites W2025152702 @default.
• W1552873049 cites W2062156645 @default.
• W1552873049 cites W2101291881 @default.
• W1552873049 cites W2111820685 @default.
• W1552873049 cites W2117698357 @default.
• W1552873049 cites W2127292942 @default.
• W1552873049 cites W2139609632 @default.
• W1552873049 cites W2151906880 @default.
• W1552873049 cites W2169991720 @default.
• W1552873049 doi "https://doi.org/10.1111/j.1432-2277.2008.00811.x" @default.
• W1552873049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19040487" @default.
• W1552873049 hasPublicationYear "2008" @default.
• W1552873049 type Work @default.
• W1552873049 sameAs 1552873049 @default.
• W1552873049 citedByCount "9" @default.
• W1552873049 countsByYear W15528730492013 @default.
• W1552873049 countsByYear W15528730492015 @default.
• W1552873049 countsByYear W15528730492017 @default.
• W1552873049 countsByYear W15528730492019 @default.
• W1552873049 countsByYear W15528730492023 @default.
• W1552873049 crossrefType "journal-article" @default.
• W1552873049 hasAuthorship W1552873049A5015978541 @default.
• W1552873049 hasAuthorship W1552873049A5025700937 @default.
• W1552873049 hasAuthorship W1552873049A5066528943 @default.
• W1552873049 hasAuthorship W1552873049A5074388120 @default.
• W1552873049 hasAuthorship W1552873049A5076879743 @default.
• W1552873049 hasConcept C126189478 @default.
• W1552873049 hasConcept C126322002 @default.
• W1552873049 hasConcept C126894567 @default.
• W1552873049 hasConcept C159641895 @default.
• W1552873049 hasConcept C2777921159 @default.
• W1552873049 hasConcept C2779561371 @default.
• W1552873049 hasConcept C2779609443 @default.
• W1552873049 hasConcept C2779699572 @default.
• W1552873049 hasConcept C2780091579 @default.
• W1552873049 hasConcept C2909675724 @default.
• W1552873049 hasConcept C2911091166 @default.
• W1552873049 hasConcept C71924100 @default.
• W1552873049 hasConcept C90924648 @default.
• W1552873049 hasConceptScore W1552873049C126189478 @default.
• W1552873049 hasConceptScore W1552873049C126322002 @default.
• W1552873049 hasConceptScore W1552873049C126894567 @default.
• W1552873049 hasConceptScore W1552873049C159641895 @default.
• W1552873049 hasConceptScore W1552873049C2777921159 @default.
• W1552873049 hasConceptScore W1552873049C2779561371 @default.
• W1552873049 hasConceptScore W1552873049C2779609443 @default.
• W1552873049 hasConceptScore W1552873049C2779699572 @default.
• W1552873049 hasConceptScore W1552873049C2780091579 @default.
• W1552873049 hasConceptScore W1552873049C2909675724 @default.
• W1552873049 hasConceptScore W1552873049C2911091166 @default.
• W1552873049 hasConceptScore W1552873049C71924100 @default.
• W1552873049 hasConceptScore W1552873049C90924648 @default.
• W1552873049 hasIssue "5" @default.
• W1552873049 hasLocation W15528730491 @default.
• W1552873049 hasLocation W15528730492 @default.
• W1552873049 hasOpenAccess W1552873049 @default.
• W1552873049 hasPrimaryLocation W15528730491 @default.
• W1552873049 hasRelatedWork W1978939233 @default.
• W1552873049 hasRelatedWork W1997245814 @default.
• W1552873049 hasRelatedWork W2009735756 @default.
• W1552873049 hasRelatedWork W2071667523 @default.
• W1552873049 hasRelatedWork W2512460450 @default.
• W1552873049 hasRelatedWork W2736541053 @default.
• W1552873049 hasRelatedWork W2765214489 @default.
• W1552873049 hasRelatedWork W2792710416 @default.
• W1552873049 hasRelatedWork W2884207731 @default.
• W1552873049 hasRelatedWork W4213432307 @default.
• W1552873049 hasVolume "22" @default.
• W1552873049 isParatext "false" @default.
• W1552873049 isRetracted "false" @default.
• W1552873049 magId "1552873049" @default.
• W1552873049 workType "article" @default.